Start here if you're new
what it is
Adicet is trying to build off-the-shelf immune-cell treatments for autoimmune disease and cancer.
how it gets paid
There is still no collaboration or product revenue in recent quarters—P&L is R&D + G&A, with small interest income (see filings).
what just happened
Q3’25 net loss was $(0.29) per diluted share; nine months 2025 YTD was $(0.94)—still pre-revenue.
At a glance
C++ balance sheet — some cracks in the foundation
40/100 earnings predictability — expect surprises
$(1.33) FY2024 GAAP EPS (diluted)
$(0.94) YTD EPS · nine months ended Sep 30, 2025
1.5 beta
xvary composite: 27/100 — weak
What they do
Adicet is trying to build off-the-shelf immune-cell treatments for autoimmune disease and cancer.
You are not buying a mature drug seller—you are buying ADI-001 (autoimmune + oncology angles) and ADI-270 (solid tumor), with value tied to clinical data. The ~$69M equity cap leaves little cushion if financing or readouts disappoint.
How they make money
n/a
annual revenue
The products that matter
phase 1 gamma delta cell therapy
ADI-001
Phase 1 · autoimmune + NHL; LN/SLE data flow 2025–26
The Nov 5, 2025 release flagged positive preliminary LN/SLE data (Oct 2025 cut) and guided an FDA meeting in 1Q2026 plus further LN/SLE/SSc updates in 1H2026—timeline is filing-driven, not guesswork.
binary readout
pre-commercial research platform
Clinical Pipeline
$0 product revenue today
you are not buying an approved portfolio. you are funding a platform that still has zero commercial revenue, which means every future dollar depends on clinical proof first.
proof before sales
Key numbers
$7.25
share price
You pay $7.25 for a stock with a $69M market cap. That is a tiny equity base and a fast-moving tape.
$(1.33)
FY2024 GAAP EPS
Full-year 2024 net loss ~$117.1M → $(1.33) diluted EPS in the year-end release tables.
1.5
beta
Beta of 1.5 means the stock has moved 50% more than the market. That is a rough ride for a $69M name.
~$103M
cash + ST investments
Sep 30, 2025 balance sheet (10-Q) plus ~$74.8M net from the Oct 2025 offering—runway narrative is in the Nov 5, 2025 press release.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- liquidity focus pre-revenue — track cash, burn, and post-quarter financings (see 10-Q / releases)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for ACET right now.
source: institutional data · return history unavailable
What just happened
Q3 2025 filed
Q3’25 net loss $(0.29) / diluted share; no product revenue.
Nine months 2025: net loss $(0.94) per diluted share; operating expenses still dominated by R&D + G&A (Adicet Nov 5, 2025 release / 10-Q).
$0
product revenue
$(0.29)
Q3 EPS
$(0.94)
9M YTD EPS
the number that mattered
$0 commercial revenue + a defined clinical calendar = the equity is still an rNPV-of-data trade until a product exists.
source: Adicet Q3 2025 release · FY2024 via FY2024 summary
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is phase 1 disappointment in ADI-001 for lymphoma.
med
ADI-001 fails to impress
ADI-001 is still in Phase 1, and the first meaningful data point is expected in H2 2026. If efficacy or safety disappoints, the core asset behind the $69M equity story gets repriced fast.
The equity case is concentrated in one readout. Weak data would pressure most of the remaining valuation.
med
cash burn outruns patience
A full-year net loss of ~$117.1M (FY2024) with zero commercial revenue means funding has to come from the balance sheet or new capital—fine until the market asks for a discount.
A dilutive raise before credible data would shift value from current holders to whoever funds the next chapter.
med
one asset, one clock, one narrative
This page names one clinical asset that matters: ADI-001. When a company has no approved products and one visible catalyst, delays can hurt almost as much as outright failure.
Zero commercial revenue means 100% of the current thesis rests on pipeline progress, not business diversification.
Zero commercial revenue, a ~$117M FY2024 net loss, and a ~$69M market cap make this a science-and-financing story first—there is no second profit engine yet.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
ADI-001 initial Phase 1 data
Next visible windows include 1H2026 clinical updates called out in the Nov 5, 2025 release (LN/SLE/SSc)—treat any single date as guidance until the company updates the calendar.
cash burn
losses versus market value
A ~$117M FY2024 net loss against a ~$69M market cap is not a rounding error—watch whether quarterly losses shrink or keep outrunning equity value.
balance sheet
financing risk before proof
With zero product revenue, every quarter also doubles as a runway update. If capital needs show up before data does, dilution moves to the front of the story.
sentiment
whether the stock can reclaim credibility
At $7.25, ACET is much closer to the $6 low than the $17 high. Price is not proof, but it is a real-time vote on how much the market believes the timeline.
Analyst rankings
earnings predictability
40 / 100
in human-speak, analysts do not have a stable operating business to model here — expect noisy numbers and revisions.
beta
1.5
beta measures market sensitivity. ACET has historically moved more than the market, which fits a small-cap biotech with one major catalyst.
risk rank
5
a rank of 5 means safer than just 5% of stocks. Translation: this sits near the risky end of the market.
source: institutional data
Institutional activity
institutional ownership data for ACET is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$7
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive